Wall Street analysts expect Johnson & Johnson (NYSE:JNJ) to announce earnings of $2.10 per share for the current quarter, Zacks reports. Three analysts have issued estimates for Johnson & Johnson’s earnings, with estimates ranging from $1.99 to $2.15. Johnson & Johnson posted earnings per share of $2.06 during the same quarter last year, which would indicate a positive year-over-year growth rate of 1.9%. The business is expected to report its next earnings results on Tuesday, April 16th.
On average, analysts expect that Johnson & Johnson will report full year earnings of $8.57 per share for the current fiscal year, with EPS estimates ranging from $8.50 to $8.60. For the next financial year, analysts forecast that the firm will report earnings of $9.23 per share, with EPS estimates ranging from $9.19 to $9.30. Zacks’ EPS averages are an average based on a survey of research analysts that follow Johnson & Johnson.
Get Johnson & Johnson alerts:Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, January 22nd. The company reported $1.97 EPS for the quarter, topping the consensus estimate of $1.95 by $0.02. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The company had revenue of $20.39 billion for the quarter, compared to the consensus estimate of $20.27 billion. During the same period in the previous year, the firm earned $1.74 earnings per share. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis.
Several research analysts recently commented on JNJ shares. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research note on Tuesday, November 20th. ValuEngine raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Thursday, December 13th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Finally, Barclays reaffirmed an “equal weight” rating and issued a $135.00 target price (down from $137.00) on shares of Johnson & Johnson in a research note on Wednesday, January 23rd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $142.81.
In related news, Director Charles Prince purchased 2,000 shares of the business’s stock in a transaction that occurred on Friday, December 14th. The shares were acquired at an average price of $134.37 per share, for a total transaction of $268,740.00. Following the completion of the acquisition, the director now directly owns 28,520 shares in the company, valued at approximately $3,832,232.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Ronald A. Kapusta sold 3,643 shares of Johnson & Johnson stock in a transaction on Thursday, December 13th. The shares were sold at an average price of $147.31, for a total transaction of $536,650.33. Following the completion of the sale, the chief accounting officer now owns 13,641 shares in the company, valued at approximately $2,009,455.71. The disclosure for this sale can be found here. Insiders own 0.22% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Evolution Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $40,000. Crewe Advisors LLC boosted its stake in Johnson & Johnson by 75.0% in the 4th quarter. Crewe Advisors LLC now owns 350 shares of the company’s stock worth $45,000 after purchasing an additional 150 shares in the last quarter. Horan Securities Inc. boosted its stake in Johnson & Johnson by 122.3% in the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after purchasing an additional 241 shares in the last quarter. Stuart Chaussee & Associates Inc. boosted its stake in Johnson & Johnson by 20.7% in the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after purchasing an additional 80 shares in the last quarter. Finally, Ruggie Capital Group raised its position in Johnson & Johnson by 342.5% in the 4th quarter. Ruggie Capital Group now owns 469 shares of the company’s stock worth $60,000 after buying an additional 363 shares during the last quarter. Institutional investors and hedge funds own 66.16% of the company’s stock.
Shares of NYSE JNJ traded down $0.85 during mid-day trading on Thursday, hitting $138.24. The stock had a trading volume of 6,098,258 shares, compared to its average volume of 6,677,139. The company has a quick ratio of 1.40, a current ratio of 1.47 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.99. The company has a market cap of $366.48 billion, a price-to-earnings ratio of 16.90, a PEG ratio of 2.18 and a beta of 0.68.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 12th. Investors of record on Tuesday, February 26th will be issued a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.60%. The ex-dividend date of this dividend is Monday, February 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 44.01%.
Johnson & Johnson announced that its board has authorized a stock repurchase plan on Monday, December 17th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 1.5% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: How to read a candlestick chart
Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment